Cite
APA Citation
Lim, J., Samuelsen, C., Golembesky, A., Shrestha, S., Wang, L., & Griebsch, I. (2019). duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future oncology, 15, 1493–1504. http://access.bl.uk/ark:/81055/vdc_100166969481.0x000003